Activation of common antiviral pathways can potentiate inflammatory responses to septic shock

Shock

Volumn 26, Issue 2, 2006, Pages 187-194

  Doughty, Lesley A ^a,b   Carlton, Stacey ^a   Galen, Benjamin ^a   Cooma Ramberan, Indranie ^a   Chung, Chung Shiang ^a   Ayala, Alfred ^a  

^a RHODE ISLAND HOSPITAL   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Bacterial infection; Cytokines; Endotoxin shock; Rodent; Viral infection

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON INDUCING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PARTHENOLIDE; POLYINOSINIC POLYCYTIDYLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; INFLAMMATION; LETHALITY; MALE; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; SEPTIC SHOCK; UPREGULATION; VIRUS INFECTION;

ANIMALS; ANTIVIRAL AGENTS; BACTERIAL INFECTIONS; CYTOKINES; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; INFLAMMATION; INTERFERON-ALPHA; INTERFERON-BETA; LEUKOCYTE COUNT; LIPOPOLYSACCHARIDES; MACROPHAGES, PERITONEAL; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; NF-KAPPA B; PERITONEAL CAVITY; POLY I-C; RECEPTOR, INTERFERON ALPHA-BETA; RECEPTORS, INTERFERON; SHOCK, SEPTIC; TUMOR NECROSIS FACTOR-ALPHA; VIRUS DISEASES;

EID: 33746716221     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000223129.79759.74     Document Type: Article

References (54)

1. Ray GC: Influenza, respiratory syncytial, adenovirus, and other respiratory viruses. In Ryan KJ (ed.): Sherris Medical Microbiology: An Introduction to Infectious Diseases. East Norwalk, CT: Appleton and Lange Paramount Publishing Business and Professional Group, p 456, 1994.
2. MacDonald KL, Osterholm MT, Hedberg CW, Shrock CG, Peterson-Jensen JM, Leonard SA, Schlievert PM: Toxic shock syndrome: a newly recognized complication of influenza and influenza-like illness. JAMA 257:1053-1058, 1987.
3. Degre M, Glasgow LA: Synergistic effect in viral-bacterial infection. I. Combined infection of the respiratory tract in mice with parainfluenza virus and Haemophilus influenzae. J Infect Dis 118:449-462, 1968.
4. Large MK, Kittlesen DJ: Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence. J Immunol 162:931-938, 1999.
5. Leung WC, Hashimoto K: Modification of susceptibility to K. pneumoniae during murine cytomegalovirus infection. Microbiol Immunol 30:761-776, 1986.
6. Schneider-Schaulies S, Niewiesk S, Schneider-Schaulies J, Meulen VT: Measles virus induced immunosuppression: targets and effector mechanisms. Curr Mol Med 1:163-181, 2001.
7. Yao ZQ, Ray S, Eisen-Vandervelde A, Waggoner S, Hahn YS: Hepatitis C virus: immunosuppression by complement regulatory pathway. Viral Immunol 14:277-295, 2001.
8. Jones WT, Menna JH, Wennerstrom DE: Lethal synergism induced in mice by influenza type A and type Ia group B streptococci. Infect Immun 41:618-621, 1983.
9. Zerr DM, Alexander ER, Duchin JS, Koutsky LA, Rubens CE: A case-control study of necrotizing fasciitis during primary varicella. Pediatrics 103:783-790, 1999.
10. Zhang WJ, Sarawar S, Nguyen P, Daly K, Rehg JE, Doherty PC, Woodland DL, Blackman MA: Lethal synergism between influenza infection and staphylococcal enterotoxin B in mice. J Immunol 157:5049-5060, 1996.
11. Sarawar S, Blackman MA, Doherty PC: Superantigen shock in mice with inapparent viral infection. J Infect Dis 170:1189-1194, 1994.
12. Nguyen KB, Biron CA: Synergism for cytokine-mediated disease during concurrent endotoxin and viral challenges: roles for NK and T cell IFN-γ production. J Immunol 62:5238-5246, 1999.
13. Fejer G, Szalay K, Gyory I, Fejes M, Kusz E, Nedieanu S, Pali T, Schmidt T, Siklodi B, Lazar G Jr, et al: Adenovirus infection dramatically augments lipopolysaccharide-induced TNF production and sensitizes to lethal shock. J Immunol 175:1498-1506, 2005.
14. Nansen A, Christensen JP, Marker O, Thomsen AR: Sensitization to lipopolysaccharide in mice with asymptomatic viral infection: the role of T cell dependent production of interferon γ. J Infect Dis 176:151-157, 1997.
15. Doughty L, Nguyen KB, Durbin JE, Biron CA: A role for IFNα/β in virus infection-induced sensitization to endotoxin. J Immunol 166:2658-2664, 2001.
16. Gendrel D, Raymond J, Coste J, Moulin F, Lorrot M, Guerin S, Ravilly S, Lefervre H, Royer C, Lacombe C, et al: Comparison of procalcitonin with C-reactive protein, interleukin 6 and interferon-alpha for differentiation of bacterial vs. viral infections. Pediatr Infect Dis J 18:875-881, 1999.
17. Moulin F, Raymond J, Iniguez J, Ravilly S, Lebon P, Gendrel D: Serum alpha-interferon in lower respiratory tract infections of children. Pediatr Infect Dis J 15:883-886, 1996.
18. Hubbard W, Choudhry M, Schwacha M, Kerby J, Rue L, Bland K, Chaudry I: Cecal ligation and puncture. Shock 24:52-57, 2005.
19. Wichterman KA, Chaudry IH: Sepsis and septic shock - a review of laboratory models and a proposal. J Surg Res 29:189-201, 1980.
20. Fink MP: Laboratory models of sepsis and septic shock. J Surg Res 49:186-196, 1990.
21. Remick DG, Newcomb DE, Bolgos GE, Call DR: Comparison of the mortality and inflammatory response of two models of sepsis. Shock 13:110-116, 2000.
22. Ebong S, Call D, Nemzek J, Bolgos G, Remick DN: Immunopathologic alterations in murine models of sepsis of increasing severity. Infect Immun 67:6603-6610, 1999.
23. Beutler B, Milsark IW, Cerami AC: Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229:869-871, 1985.
24. Howard M, Muchamuel T, Andrade S, Menon S: Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 177:1205-1208, 1993.
25. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC: Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348:550-552, 1990.
26. Eskandari M, Bolgos G, Miller C, Nguyen D, DeForge LE, Remick DG: Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol 148:2724-2730, 1992.
27. Remick D, Garg SJ, Newcomb DE, Wollenberg G, Huie TK, Bolgos GL: Exogenous interleukin-10 fails to decrease the mortality or morbidity of sepsis. Crit Care Med 26:895-904, 1998.
28. Garcia P, Mancilla J, Dinarello CA: The interleukin-1 receptor antagonist can either reduce or exaggerated lethality of Klebsiella pneumoniae sepsis in newborn rats. Infect Immun 61:926-932, 1993.
29. Latifi SQ, O'Riordan MA, Levine AD: Interleukin-10 controls the onset of irreversible septic shock. Infect Immun 70:4441-4446, 2002.
30. Majde JA: Viral double-stranded RNA, cytokines, and the flu. J Interferon Cytokine Res 20:259-272, 2000.
31. Malmgard L, Salazar-Mather T, Lewis C, Biron C: Promotion of alpha/beta interferon induction during in vivo viral infection through alpha/beta interferon receptor/STAT1 system-dependent and -independent pathways. J Virol 76:4520-4525, 2002.
32. Ishikawa R, Biron CA: IFN induction and associated changes in splenic leukocyte distribution. J Immunol 150:3713-3727, 1993.
33. Maggi LB, Heitmeier MR, Scheuner D, Kaufman RJ, Buller RM, Corbett JA: Potential role of PKR in double-stranded RNA-induced macrophage activation. EMBO J 19:3630-3638, 2000.
34. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, Takeuchi O, Sugiyama M, Okabe M, Takeda K, et al: Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science 301:640-643, 2003.
35. Durbin JE, Hackenmiller R, Simon MC, Levy DE: Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84:443-450, 1996.
36. Jacobs B, Langland J: When two strands are better than one: the mediators and modulators of the cellular response to double stranded RNA. Virology 219:339-349, 1996.
37. Katze MG, HE Y, Gale M: Viruses and interferon: a fight for supremacy. Nat Rev Immunol 2:675-687, 2002.
38. Biron CA: Interferons α and β as immune regulators - a new look. Immunity 14:661-664, 2001.
39. Hoebe K, Du X, Georgel P, Janssen E, Tabeta K, Kim SO, Goode J, Lin P, Mann N, Mudd S, et al: Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 424:743-748, 2003.
40. Jiang Z, Mak TW, Sen G, Li X: Toll-like receptor 3-mediated activation of NFκB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN-β. Proc Natl Acad Sci U S A 101:3533-3538, 2004.
41. Hehner SP, Heinrich M, Bork PM, Vogt M, Ratter F, Lehmann V, Schulze-Osthoff K, Droge W, Schmitz ML: Sesquiterpene lactones specifically inhibit activation of NFκB by preventing the degradation of IκBα and IκBβ. J Biol Chem 273:1288-1297, 1998.
42. Hehner SP, Hofmann TG, Droge W, Schmitz ML: The anti-inflammatory sesquiterpene lactone parthenolide inhibits NFκB by targeting the IκB kinase complex. J Immunol 163:5617-5623, 1999.
43. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, Coyle AJ, Liao SM, Maniatis T: IKKα and TBK I are essential components of the IRF3 signaling pathway. Nature 4:491-496, 2003.
44. Sharma S, tenOever BR, Grandvaux N, Zhou GP, Lin R, Hiscott J: Triggering the interferon antiviral response through an IKK-related pathway. Science 300:1148-1151, 2003.
45. Karaghiosoff M, Steinborn R, Kovarik P, Kriegshauser G, Baccarini M, Donabauer B, Reichart U, Kolbe T, Bogdan C, Leanderson T, et al: Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock. Nat Immunol 4:471-477, 2003.
46. Sunden-Cullberg J, Norrby-Teglund A, Rouhiainen A, Rauvala H, Herman G, Tracey K, Lee M, Andersson J, Tokics L, Treutiger C: Persistent elevation of high mobility group box-1 protein (HMGB-1) in patients with severe sepsis and septic shock. Crit Care Med 33:564-573, 2005.
47. Panacek E, Marshall JC, Albertson TE, Johnson DH, Johnson S, MacArthur RD, Miller M, Barchuk WT, Fischkoff S, Kaul M, et al: Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody (Fab)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 32:2173-2182, 2004.
48. Casey L, Balk R, Bone R: Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 119:771-778, 1993.
49. Agarwal SK, Marshall GD: Beta-adrenergic modulation of human type-1/type-2 cytokine balance. J Allergy Clin Immunol 105:91-98, 2000.
50. Bhaskaram P: Micronutrient, malnutrition, infection and immunity. Nutr Rev 60:S40-S45, 2002.
51. Chrousos G: The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 332:1351-1362, 1995.
52. Lord G, Matarese G, Howard J, Baker R, Bloom S, Lechler R: Leptin modulates the T cell immune response and reverses starvation-induced immunosuppression. Nature 394:897-901, 1998.
53. Nelson C, Lysle D: Severity, time, and beta-adrenergic receptor involvement in surgery-induced immune alterations. J Surg Res 80:115-122, 1998.
54. Plata-Salaman C: Brain injury and immunosuppression. Nat Med 4: 768-769, 1998.